New River Pharmaceuticals named James Shaffer as VP of sales and marketing to oversee the anticipated launch of the company's attention deficit-hyperactivity disorder (ADHD) drug Vyvanse.
Shaffer joins New River from Prestwick Pharmaceuticals. Shaffer served as senior director, commercial operations at Prestwick since 2004. Prior to that, he worked at Intermune as national sales director.
New River will co-market Vyvanse along with Shire. Vyvanse is expected to follow in the footsteps of Shire's ADHD market-leading Adderall XR but is formulated to be harder to abuse.